Core Viewpoint - The stock of Giant Bio (02367) has experienced a decline of over 6%, currently trading at 39.8 HKD, with a transaction volume of 513 million HKD, following the approval of its medical device product [1] Group 1: Company Developments - Giant Bio's "Recombinant Type I α1 Collagen Lyophilized Fiber" has received approval as a Class III medical device, marking it as China's first recombinant Type I natural sequence collagen facial injection product [1] - Huatai Securities maintains its profit forecast for Giant Bio, projecting a net profit for the parent company in 2025-2027 [1] Group 2: Market Performance - Zheshang International reports that the online sales performance of Kefu Beauty during the first phase of the Double Eleven shopping festival was relatively weak, estimating a 10% year-on-year decline in online revenue for the second half of the year [1] - Keli Jin is expected to achieve approximately 40% high growth in annual online revenue, while offline business is projected to maintain steady growth [1] - The revenue growth forecast for the company is expected to slow down to 12% by 2025 [1]
港股异动 | 巨子生物(02367)午后跌超6% 医美新品由获批至上市推广仍需一定筹备时间